{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:08:31Z","timestamp":1791666511112,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515140145"],"award-info":[{"award-number":["2023A1515140145"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Huizhou Science and Technology Innovation Team Project","award":["2023EQ050012"],"award-info":[{"award-number":["2023EQ050012"]}]},{"name":"Guangzhou Medical University Research Ability Enhancement Project","award":["2024SRP215"],"award-info":[{"award-number":["2024SRP215"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11060-025-05160-4","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:46:45Z","timestamp":1753253205000},"page":"857-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I\/II study"],"prefix":"10.1007","volume":"175","author":[{"given":"Zhenyu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingru","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"5160_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/s1470-2045(10)70034-6","volume":"11","author":"P Beauchesne","year":"2010","unstructured":"Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11:871\u2013879. https:\/\/doi.org\/10.1016\/s1470-2045(10)70034-6","journal-title":"Lancet Oncol"},{"key":"5160_CR2","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rud\u00e0 R, Preusser M (2017) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28:iv84\u2013iv99. https:\/\/doi.org\/10.1093\/annonc\/mdx221","journal-title":"Ann Oncol"},{"key":"5160_CR3","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","volume":"26","author":"JA Wilcox","year":"2024","unstructured":"Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P, Garzia L, Glantz M, Oliva ICG, Kumthekar P, Le Rhun E, Nagpal S, O\u2019Brien B, Pentsova E, Lee EQ, Remsik J, Rud\u00e0 R, Smalley I, Taylor MD, Weller M, Wefel J, Yang JT, Young RJ, Wen PY, Boire AA (2024) Leptomeningeal metastases from solid tumors: A society for Neuro-Oncology and American society of clinical oncology consensus review on clinical management and future directions. Neuro Oncol 26:1781\u20131804. https:\/\/doi.org\/10.1093\/neuonc\/noae103","journal-title":"Neuro Oncol"},{"key":"5160_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200544010-00001","volume":"44","author":"G Fleischhack","year":"2005","unstructured":"Fleischhack G, Jaehde U, Bode U (2005) Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44:1\u201331. https:\/\/doi.org\/10.2165\/00003088-200544010-00001","journal-title":"Clin Pharmacokinet"},{"key":"5160_CR5","doi-asserted-by":"publisher","first-page":"e000507","DOI":"10.1136\/esmoopen-2019-000507","volume":"4","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun E, Preusser M, van den Bent M, Andratschke N, Weller M (2019) How we treat patients with leptomeningeal metastases. ESMO Open 4:e000507. https:\/\/doi.org\/10.1136\/esmoopen-2019-000507","journal-title":"ESMO Open"},{"key":"5160_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3389\/fonc.2019.00838","volume":"9","author":"Z Pan","year":"2019","unstructured":"Pan Z, Yang G, Cui J, Li W, Li Y, Gao P, Jiang T, Sun Y, Dong L, Song Y, Zhao G (2019) A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from Non-small-cell lung Cancer. Front Oncol 9:838. https:\/\/doi.org\/10.3389\/fonc.2019.00838","journal-title":"Front Oncol"},{"key":"5160_CR7","doi-asserted-by":"publisher","first-page":"175883592093795","DOI":"10.1177\/1758835920937953","volume":"12","author":"Z Pan","year":"2020","unstructured":"Pan Z, Yang G, He H, Cui J, Li W, Yuan T, Chen K, Jiang T, Gao P, Sun Y, Cong X, Li Z, Wang Y, Pang X, Song Y, Zhao G (2020) Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I\/II study. Ther Adv Med Oncol 12:1758835920937953. https:\/\/doi.org\/10.1177\/1758835920937953","journal-title":"Ther Adv Med Oncol"},{"key":"5160_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T (2021) Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase Inhibitor-Failed leptomeningeal metastases from EGFR-Mutant NSCLC-a prospective, Open-Label, Single-Arm phase 1\/2 clinical trial (Unique identifier: ChiCTR1800016615). J Thorac Oncol 16:1359\u20131368. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.018","journal-title":"J Thorac Oncol"},{"key":"5160_CR9","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.cllc.2022.11.011","volume":"24","author":"H Li","year":"2023","unstructured":"Li H, Zheng S, Lin Y, Yu T, Xie Y, Jiang C, Liu X, Qian X, Yin Z (2023) Safety, Pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective phase I study. Clin Lung Cancer 24:e94\u2013e104. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.011","journal-title":"Clin Lung Cancer"},{"key":"5160_CR10","doi-asserted-by":"publisher","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","volume":"9","author":"C Fan","year":"2024","unstructured":"Fan C, Jiang Z, Teng C, Song X, Li L, Shen W, Jiang Q, Huang D, Lv Y, Du L, Wang G, Hu Y, Man S, Zhang Z, Gao N, Wang F, Shi T, Xin T (2024) Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR\u2009+\u2009NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open 9:102384. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102384","journal-title":"ESMO Open"},{"key":"5160_CR11","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.jtho.2021.09.020","volume":"17","author":"Z Pan","year":"2022","unstructured":"Pan Z (2022) Focusing on intrathecal pemetrexed for treating leptomeningeal metastases from NSCLC. J Thorac Oncol 17:e31\u2013e32. https:\/\/doi.org\/10.1016\/j.jtho.2021.09.020","journal-title":"J Thorac Oncol"},{"key":"5160_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00280-010-1522-7","volume":"68","author":"JM Sun","year":"2011","unstructured":"Sun JM, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ (2011) Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother Pharmacol 68:531\u2013538. https:\/\/doi.org\/10.1007\/s00280-010-1522-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"5160_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/neuonc\/now183","volume":"19","author":"M Chamberlain","year":"2016","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Rud\u00e0 R, Raizer J, Boogerd W, Taillibert S, Groves MD, Rhun EL, Walker J, van den Bent M, Wen PY, Jaeckle KA (2016) Leptomeningeal metastases: a RANO proposal for response criteria. Neurooncology 19:484\u2013492. https:\/\/doi.org\/10.1093\/neuonc\/now183","journal-title":"Neurooncology"},{"key":"5160_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/neuonc\/noz024","volume":"21","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rud\u00e0 R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winklhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, Van den Bent M, Wen PY, Bendszus M, Weller M (2019) The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol 21:648\u2013658. https:\/\/doi.org\/10.1093\/neuonc\/noz024","journal-title":"Neuro Oncol"},{"key":"5160_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/jco.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ (2020) Osimertinib in patients with epidermal growth factor receptor Mutation-Positive Non-Small-Cell lung Cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 38:538\u2013547. https:\/\/doi.org\/10.1200\/jco.19.00457","journal-title":"J Clin Oncol"},{"key":"5160_CR16","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cncr.26709","volume":"118","author":"JJ Raizer","year":"2012","unstructured":"Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA (2012) Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma. Cancer 118:3743\u20133748. https:\/\/doi.org\/10.1002\/cncr.26709","journal-title":"Cancer"},{"key":"5160_CR17","doi-asserted-by":"publisher","first-page":"113456","DOI":"10.1016\/j.ejca.2023.113456","volume":"197","author":"DW Lee","year":"2024","unstructured":"Lee DW, Jung KH, Lee KH, Park YH, Lee KS, Sohn J, Ahn HK, Jeong JH, Koh SJ, Kim JH, Kim HJ, Lee KE, Kim HJ, Yang YW, Park KH, Lee J, Won HS, Kim TY, Im SA (2024) Pemetrexed plus Vinorelbine versus Vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. Eur J Cancer 197:113456. https:\/\/doi.org\/10.1016\/j.ejca.2023.113456","journal-title":"Eur J Cancer"},{"key":"5160_CR18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/annonc\/mdn766","volume":"20","author":"L Celio","year":"2009","unstructured":"Celio L, Sternberg CN, Labianca R, La Torre I, Amoroso V, Barone C, Pinotti G, Cascinu S, Di Costanzo F, Cetto GL, Bajetta E (2009) Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol 20:1062\u20131067. https:\/\/doi.org\/10.1093\/annonc\/mdn766","journal-title":"Ann Oncol"},{"key":"5160_CR19","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1097\/JTO.0b013e3181fb5c3e","volume":"5","author":"A Jatoi","year":"2010","unstructured":"Jatoi A, Soori G, Foster NR, Hiatt BK, Knost JA, Fitch TR, Callister MD, Nichols FC 3rd, Husted TM, Alberts SR (2010) Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol 5:1994\u20131998. https:\/\/doi.org\/10.1097\/JTO.0b013e3181fb5c3e","journal-title":"J Thorac Oncol"},{"key":"5160_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00280-012-1950-7","volume":"70","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhao L, Huang P, Wu J, Wang F, Huang Y, Zhang L (2012) Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy. Cancer Chemother Pharmacol 70:611\u2013615. https:\/\/doi.org\/10.1007\/s00280-012-1950-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"5160_CR21","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2005.02.007","volume":"32","author":"MA Socinski","year":"2005","unstructured":"Socinski MA (2005) Pemetrexed (Alimta) in small cell lung cancer. Semin Oncol 32:S1\u20134. https:\/\/doi.org\/10.1053\/j.seminoncol.2005.02.007","journal-title":"Semin Oncol"},{"key":"5160_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1124\/mol.104.009373","volume":"68","author":"E Giovannetti","year":"2005","unstructured":"Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110\u2013118. https:\/\/doi.org\/10.1124\/mol.104.009373","journal-title":"Mol Pharmacol"},{"key":"5160_CR23","doi-asserted-by":"publisher","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","volume":"8","author":"E Le Rhun","year":"2023","unstructured":"Le Rhun E, Weller M, van den Bent M, Brandsma D, Furtner J, Rud\u00e0 R, Schadendorf D, Seoane J, Tonn JC, Wesseling P, Wick W, Minniti G, Peters S, Curigliano G, Preusser M (2023) Leptomeningeal metastasis from solid tumours: EANO-ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open 8:101624. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101624","journal-title":"ESMO Open"},{"key":"5160_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1148\/radiology.216.3.r00au37672","volume":"216","author":"E Courchesne","year":"2000","unstructured":"Courchesne E, Chisum HJ, Townsend J, Cowles A, Covington J, Egaas B, Harwood M, Hinds S, Press GA (2000) Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology 216:672\u2013682. https:\/\/doi.org\/10.1148\/radiology.216.3.r00au37672","journal-title":"Radiology"},{"key":"5160_CR25","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/cncr.21828","volume":"106","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Phase II trial of intracerebrospinal fluid Etoposide in the treatment of neoplastic meningitis. Cancer 106:2021\u20132027. https:\/\/doi.org\/10.1002\/cncr.21828","journal-title":"Cancer"},{"key":"5160_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1215\/15228517-2007-059","volume":"10","author":"MD Groves","year":"2008","unstructured":"Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK (2008) A multicenter phase II trial of intrathecal Topotecan in patients with meningeal malignancies. Neuro Oncol 10:208\u2013215. https:\/\/doi.org\/10.1215\/15228517-2007-059","journal-title":"Neuro Oncol"},{"key":"5160_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamaoncol.2024.1299","volume":"10","author":"KA Ahmed","year":"2024","unstructured":"Ahmed KA, Kumthekar PU, Pina Y, Kim Y, Vogelbaum MA, Han HS, Forsyth PA (2024) Radiation therapy followed by intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive breast leptomeningeal disease: A phase 1 nonrandomized controlled trial. JAMA Oncol 10:984\u2013986. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1299","journal-title":"JAMA Oncol"},{"key":"5160_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3760\/cma.j.cn112152-20200711-00647","volume":"44","author":"ZY Pan","year":"2022","unstructured":"Pan ZY, Song YY, Jiang TC, Yang X, Yang GZ (2022) [Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors]. Zhonghua Zhong Liu Za Zhi 44:112\u2013119. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20200711-00647","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"5160_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12885-023-10676-x","volume":"23","author":"Z Xu","year":"2023","unstructured":"Xu Z, Hao X, Wang Q, Yang K, Li J, Xing P (2023) Intracranial efficacy and safety of Furmonertinib 160\u00a0mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy. BMC Cancer 23:206. https:\/\/doi.org\/10.1186\/s12885-023-10676-x","journal-title":"BMC Cancer"},{"key":"5160_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","volume":"31","author":"S Park","year":"2020","unstructured":"Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ (2020) A phase II, multicenter, two cohort study of 160\u00a0mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 31:1397\u20131404. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.017","journal-title":"Ann Oncol"},{"key":"5160_CR31","doi-asserted-by":"publisher","first-page":"1233198","DOI":"10.3389\/fonc.2023.1233198","volume":"13","author":"T Chen","year":"2023","unstructured":"Chen T, Chen J, Liu DS, Shu YL, Fu MY, Gou HJ, Lei KJ, Jia YM (2023) Successful therapy using high-dose Furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review. Front Oncol 13:1233198. https:\/\/doi.org\/10.3389\/fonc.2023.1233198","journal-title":"Front Oncol"},{"key":"5160_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","volume":"15","author":"MJ Ahn","year":"2020","unstructured":"Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T (2020) Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-Positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 15:637\u2013648. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.113","journal-title":"J Thorac Oncol"},{"key":"5160_CR33","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/jco.24.00708","volume":"42","author":"S Park","year":"2024","unstructured":"Park S, Baldry R, Jung HA, Sun JM, Lee SH, Ahn JS, Kim YJ, Lee Y, Kim DW, Kim SW, Lee KH, Lee WJ, Choi JW, Chong K, Lee JI, Gwon SH, Son NH, Ahn MJ (2024) Phase II efficacy and safety of 80\u00a0mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor Mutation-Positive Non-Small cell lung Cancer (BLOSSOM). J Clin Oncol 42:2747\u20132756. https:\/\/doi.org\/10.1200\/jco.24.00708","journal-title":"J Clin Oncol"},{"key":"5160_CR34","doi-asserted-by":"publisher","first-page":"877279","DOI":"10.3389\/fonc.2022.877279","volume":"12","author":"H Zhang","year":"2022","unstructured":"Zhang H, Wang Y, Wu H, Zhou S, Li S, Meng X, Tao R, Yu J (2022) Olaparib combined with Dacomitinib in Osimertinib-Resistant brain and leptomeningeal metastases from Non-Small cell lung cancer: A case report and systematic review. Front Oncol 12:877279. https:\/\/doi.org\/10.3389\/fonc.2022.877279","journal-title":"Front Oncol"},{"key":"5160_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-022-02387-0","volume":"20","author":"MM Zheng","year":"2022","unstructured":"Zheng MM, Li YS, Tu HY, Sun H, Yin K, Jiang BY, Yang JJ, Zhang XC, Zhou Q, Xu CR, Wang Z, Chen HJ, Zhou DX, Wu YL (2022) Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases. BMC Med 20:197. https:\/\/doi.org\/10.1186\/s12916-022-02387-0","journal-title":"BMC Med"},{"key":"5160_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 121:725\u2013737. https:\/\/doi.org\/10.1038\/s41416-019-0573-8","journal-title":"Br J Cancer"},{"key":"5160_CR37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.6004\/jnccn.2022.7006","volume":"20","author":"F Yan","year":"2022","unstructured":"Yan F, Rinn KJ, Kullnat JA, Wu AY, Ennett MD, Scott EL, Kaplan HG (2022) Response of leptomeningeal metastasis of breast Cancer with a HER2\/neu activating variant to tucatinib: A case report. J Natl Compr Canc Netw 20:745\u2013752. https:\/\/doi.org\/10.6004\/jnccn.2022.7006","journal-title":"J Natl Compr Canc Netw"},{"key":"5160_CR38","doi-asserted-by":"publisher","first-page":"811919","DOI":"10.3389\/fonc.2022.811919","volume":"12","author":"Y Chi","year":"2022","unstructured":"Chi Y, Shang M, Xu L, Gong H, Tao R, Song L, Zhang B, Yin S, Cong B, Li H (2022) Durable effect of Pyrotinib and metronomic Vinorelbine in HER2-Positive breast Cancer with leptomeningeal disease: A case report and literature review. Front Oncol 12:811919. https:\/\/doi.org\/10.3389\/fonc.2022.811919","journal-title":"Front Oncol"},{"key":"5160_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-023-00519-0","volume":"9","author":"L Alder","year":"2023","unstructured":"Alder L, Trapani D, Bradbury C, Van Swearingen AED, Tolaney SM, Khasraw M, Anders CK, Lascola CD, Hsu L, Lin NU, Sammons S (2023) Durable responses in patients with HER2\u2009+\u2009breast cancer and leptomeningeal metastases treated with trastuzumab Deruxtecan. NPJ Breast Cancer 9:19. https:\/\/doi.org\/10.1038\/s41523-023-00519-0","journal-title":"NPJ Breast Cancer"},{"key":"5160_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12885-018-3994-5","volume":"18","author":"GRR Ricciardi","year":"2018","unstructured":"Ricciardi GRR, Russo A, Franchina T, Schifano S, Mastroeni G, Santacaterina A, Adamo V (2018) Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. BMC Cancer 18:97. https:\/\/doi.org\/10.1186\/s12885-018-3994-5","journal-title":"BMC Cancer"},{"key":"5160_CR41","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/jco.1987.5.10.1655","volume":"5","author":"RN Hitchins","year":"1987","unstructured":"Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655\u20131662. https:\/\/doi.org\/10.1200\/jco.1987.5.10.1655","journal-title":"J Clin Oncol"},{"key":"5160_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7:382\u2013385. https:\/\/doi.org\/10.1097\/JTO.0b013e3182398e4f","journal-title":"J Thorac Oncol"},{"key":"5160_CR43","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.4103\/2152-7806.111304","volume":"4","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun E, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 4:S265\u2013288. https:\/\/doi.org\/10.4103\/2152-7806.111304","journal-title":"Surg Neurol Int"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05160-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05160-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:57:25Z","timestamp":1757487445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05160-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5160"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05160-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6572942\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This phase I\/II study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of the First Hospital of Jilin University, Changchun, China (Approval number: 2017\u2009\u2212\u2009246). Informed consent was obtained from all subjects. (\n                      \n                      Identifier: NCT05289908).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}